Clinical data | |
---|---|
License data | |
Pregnancy category |
|
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.217.751 |
Chemical and physical data | |
Formula | C24H33Cl2NO5 |
Molar mass | 486.43 g·mol−1 |
3D model (JSmol) | |
| |
|
Vilanterol is an ultra-long-acting β2-adrenergic receptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).[1][2] The combination is also approved for the treatment of asthma in Canada, Europe, Japan[3] and New Zealand.[4]
Vilanterol is available in following combinations:
{{cite web}}
: CS1 maint: multiple names: authors list (link)